CAPR Stock Soars As FDA Opens Door And Cantor Hikes Target

Capricor Therapeutics Inc. stocks have been trading up by 13.75 percent following bullish sentiment on its clinical trial progress.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CAPR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Wall Street upgrade and a steep price target hike have thrust CAPR onto more traders’ screens after Q2 2026.
Shares ripped roughly 80–104% on FDA openness to an amended deramiocel filing and strong market reaction to earnings.
Regulators will review new HOPE‑3 data focused on upper-limb function in Duchenne muscular dystrophy, but the PDUFA timeline is likely extended.
Q2 brought zero revenue, a wider loss, and about $238M in cash, underscoring CAPR’s single‑asset, high‑risk biotech profile.
Activist Kaos Capital is pressing Capricor’s board for strategic changes, M&A exploration, and tighter cash discipline.

Live Update At 12:33:32 EDT: On Monday, August 24, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 13.75%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CAPR has traded like a biotech rollercoaster. In early August 2026, Capricor Therapeutics sat around the mid‑$3s to low‑$4s. Then the catalyst storm hit. By 2026/08/13, CAPR closed near $4.21. The next session, after Q2 2026 earnings and regulatory headlines, the stock exploded to $6.65. Within days CAPR printed highs above $8.00 before pulling back into the mid‑$6s and now around $7.16.

For short‑term traders, that is textbook momentum: a near‑doubling from $3–4 to above $7 in under two weeks, followed by sharp intraday swings. The 5‑minute chart shows heavy volatility at the open, a flush from an $8.03 open down into the $6s, then a grind back over $7 as dip buyers stepped in.

More Breaking News

Fundamentally, Capricor Therapeutics is still pre‑revenue. Q2 2026 showed no product sales and a net loss of about $40.7M, driven mainly by $28.9M in research and $14.1M in G&A. Operating cash burn was roughly $31.5M for the quarter. The balance sheet, however, is a big reason traders keep coming back to CAPR: roughly $238M in cash, cash equivalents and short‑term investments, a current ratio near 7.4, and modest leverage give Capricor time to see the deramiocel story through. The trade is all about execution and data, not current earnings.

Why Traders Are Watching CAPR So Closely

Capricor Therapeutics has become a live‑wire ticker because multiple powerful themes hit all at once. On the clinical side, CAPR’s HOPE‑3 Phase 3 trial in Duchenne muscular dystrophy met its primary endpoint in upper‑limb function, and the data landed in The Lancet. That kind of publication gives deramiocel scientific credibility, which traders in biotech love to see.

Regulators add the real juice. After a harsh 9‑3 negative FDA advisory committee vote on deramiocel’s original cardiomyopathy indication, many assumed the door was nearly shut. Instead, CAPR secured a crucial lifeline: the FDA agreed to review an amended BLA focused on upper‑limb skeletal muscle function, built around 24‑month HOPE‑3 extension data and refined analyses. The price response was immediate. CAPR surged 80–104% in premarket and regular trading as the market recalibrated odds for approval, with shares briefly trading near $7.74.

Wall Street followed. Cantor Fitzgerald upgraded Capricor Therapeutics to Overweight from Neutral and raised its price target to $28 from $3.50, well above the prior mean target of about $26. This told traders that at least one major shop believes CAPR is deeply mispriced versus its deramiocel optionality.

At the same time, the story is getting spicier on the governance front. Activist Kaos Capital, a significant shareholder, is demanding board changes, a formal M&A and Strategic Alternatives Committee, and sharper cash preservation. Another holder filed a Schedule 13G showing a sizable but passive stake in CAPR. Together, these moves signal outside capital believes there is value to unlock, whether through approval, partnership, or a sale. For active traders, that mix of regulatory risk, analyst re‑rating, and activist pressure is exactly the kind of cocktail that fuels big multi‑day moves.

Conclusion

CAPR now trades in a classic binary‑style biotech setup: huge potential reward tied to a single late‑stage asset, deramiocel, balanced against real regulatory and execution risk. Capricor Therapeutics has no current revenue and deep losses, but it does have around $238M in cash and a disclosed runway of at least 12 months to navigate FDA discussions, arbitration with NS Pharma, and any boardroom drama.

The upgraded $28 target from Cantor Fitzgerald gives traders a clear reference point versus a stock currently around the high‑$7 area. If the amended BLA for deramiocel gains traction and a narrower upper‑limb indication wins over the FDA, the upside case that analysts are sketching out becomes easier for the market to model. If the agency pushes back again or timelines slip too far, CAPR’s recent gains can unwind just as fast.

Overlay that with Kaos Capital pushing for new directors, possible strategic deals, and a refreshed board, and CAPR becomes more than a simple data trade. It is a live case study in how science, regulation, and corporate strategy collide on a small‑cap chart.

Traders in the Tim Sykes community focus on exactly these kinds of volatile setups: clear catalysts, heavy volume, defined risk. As Tim Sykes likes to remind his students, “Volatility is opportunity, but only if you respect your risk and cut losses quickly.” That kind of disciplined approach lines up with broader trading education principles as well; as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. For CAPR, the opportunity is obvious on the chart; the discipline is up to each trader. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!